Gargano G, Fanizza G, Polignano G, Lorusso V, De Lena M
Gynaecological Division, Oncology Institute, Bari 70126, Italy.
Oncol Rep. 1999 Nov-Dec;6(6):1349-52. doi: 10.3892/or.6.6.1349.
The use of epoetin alpha and sodium ferrous gluconate has been shown to be a safe and effective treatment which can be used to avoid allogeneic blood transfusions and to plan short term elective surgery. In this study the authors submitted 20 patients, scheduled to undergo surgery for gynaecological tumors, to a program of pre-operative autologous blood donation. All the patients received both epoetin alpha and sodium ferrous gluconate in the pre- and post-donation period. Epoetin alpha was administered subcutaneously at a dose of 200 IU/kg thrice a week during the week before and after autologous blood donation (400 ml). Sodium ferrous gluconate was administered intravenously shortly before the first and fourth administration of 125 mg epoetin alpha, and shortly before the third and sixth administration of 62.5 mg epoetin alpha. Surgery was scheduled to be performed 10-15 days after the last epoetin alpha administration, i.e. within 15-20 days from blood donation. All the patients were tested for the following blood chemistry parameters: hematocrit, haemoglobin, sideraemia and ferritin at treatment start, before donation, at treatment end, before autologous blood infusion and on the third and seventh day after surgery. No patient receiving epoetin alpha required allogeneic blood transfusion, as both the hematocrit and haemoglobin values remained normal. Epoetin alpha was observed to be a safe and effective treatment to be used in autologous blood donation programs in all patients scheduled to undergo surgery. It limits the decrease of hematocrit values following autologous blood donation thus enabling all the patients, who for a variety of reasons refuse allogeneic blood infusion, to predeposit autologous blood shortly before the date scheduled for surgery.
已证明使用促红细胞生成素α和葡萄糖酸亚铁钠是一种安全有效的治疗方法，可用于避免异体输血并规划短期择期手术。在本研究中，作者让20名计划接受妇科肿瘤手术的患者参加术前自体献血计划。所有患者在献血前和献血后期间均接受促红细胞生成素α和葡萄糖酸亚铁钠治疗。在自体献血（400毫升）前后一周内，促红细胞生成素α以200 IU/kg的剂量每周皮下注射三次。在首次和第四次注射125毫克促红细胞生成素α之前不久，以及第三次和第六次注射62.5毫克促红细胞生成素α之前不久，静脉注射葡萄糖酸亚铁钠。手术安排在最后一次注射促红细胞生成素α后10 - 15天进行，即献血后15 - 20天内。对所有患者进行了以下血液化学参数检测：治疗开始时、献血前、治疗结束时、自体输血前以及术后第三天和第七天的血细胞比容、血红蛋白、血清铁和铁蛋白。接受促红细胞生成素α治疗的患者均无需异体输血，因为血细胞比容和血红蛋白值均保持正常。促红细胞生成素α被认为是一种安全有效的治疗方法，可用于所有计划接受手术患者的自体献血计划。它限制了自体献血后血细胞比容值的下降，从而使所有因各种原因拒绝异体输血的患者能够在预定手术日期前不久预先储存自体血液。
